Skip to main content
Premium Trial:

Request an Annual Quote

Cambridge Bio to Distribute, Support Chan Adverse Event Test in Europe

NEW YORK (GenomeWeb News) — Cambridge BioScience today said it will distribute and support Chan Test’s potassium channel assays in Europe.
 
Cleveland-based Chan Test’s assay, based on ion channels, is designed to predict cardiac events associated with non-cardiac drugs.
 
Cambridge BioScience Managing Director Mike Kerns said his company expects “significant growth” for the assay due to “the rapidly growing interest in ion channels as primary targets in areas such as pain and epilepsy research.”
 
Financial terms of the agreement were not released.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.